Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study
Journal of Allergy and Clinical Immunology · 2025-06 · 155 (6) · 1945-1956
DOI: 10.1016/j.jaci.2025.01.045 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-06. Verfasst von Julie McLaren und 11 weiteren Autor:innen. Beteiligte Einrichtung: Amgen Inc, Thousand Oaks, Calif. Electronic address: jmclar01@amgen.com. Hauptthemen laut MEDLINE: Chronic Urticaria, Antibodies, Monoclonal, Humanized, Anti-Allergic Agents. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca UK Limited, Amgen Inc.
Abstract (Originalsprache)
BACKGROUND: Tezepelumab, an mAb inhibiting thymic stromal lymphopoietin, is an upstream-targeted therapy with potential to inhibit multiple pathways in chronic spontaneous urticaria (CSU). OBJECTIVE: antihistamines. METHODS: This phase 2b study randomized 183 patients (125 anti-IgE therapy-naive; 58 anti-IgE therapy-experienced) to placebo every 2 weeks, tezepelumab 210 mg every 4 weeks, tezepelumab 420 mg every 2 weeks, or omalizumab 300 mg every 4 weeks (anti-IgE-naive only) for 16-week treatment. The primary end point was change from baseline in weekly Urticaria Activity Score (UAS7) at week 16. Safety and exploratory end points were evaluated through week 32. RESULTS: The 16-week primary end point was not met. In the overall population, tezepelumab 210 mg and 420 mg did not significantly improve UAS7 versus placebo (least squares mean [SE]: -13.5 [1.6] and -14.7 [1.5], respectively, vs -13.6 [1.6], P = .99, nominal and P = .60, nominal, respectively). Greater improvement in UAS7 versus placebo was observed in the anti-IgE-naive tezepelumab-treated populations (nominal significance); a trend toward significance was observed with omalizumab. In the anti-IgE-naive population, there was delayed, sustained, 32-week off-treatment improvement in UAS7 versus placebo with tezepelumab 210 mg (nominally significant) and 420 mg (trend), but not with omalizumab. This effect was larger in patients with lower baseline IgE levels and longer CSU duration and accompanied sustained IL-5 and IL-13 reductions. Tezepelumab and placebo safety findings were balanced. CONCLUSION: Although the 16-week primary end point was not met, tezepelumab showed post-treatment reductions in CSU activity through week 32, suggesting a delayed, sustained, thymic stromal lymphopoietin blockade treatment effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amgen Inc, Thousand Oaks, Calif. Electronic address: jmclar01@amgen.com.
- Amgen Inc, Thousand Oaks, Calif.
- University of Cincinnati College of Medicine, Cincinnati, Ohio.
- David Geffen School of Medicine, Los Angeles, Calif.
- Nihon University School of Medicine, Tokyo, Japan.
- McMaster University School of Medicine, Hamilton, Ontario, Canada.
Förderung
- AstraZeneca UK Limited
- Amgen Inc
Zitieren
APA
McLaren, J., Chon, Y., Gorski, K. S., Bernstein, J. A., Corren, J., Hayama, K., Jain, V., Lima, H., Sofen, H., Ponnarambil, S., Molfino, N. A., & Maurer, M. (2025). Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study. Journal of Allergy and Clinical Immunology, 155(6), 1945-1956. https://doi.org/10.1016/j.jaci.2025.01.045
Vancouver
McLaren J, Chon Y, Gorski KS, Bernstein JA, Corren J, Hayama K, et al. Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study. Journal of Allergy and Clinical Immunology. 2025;155(6):1945-1956. doi:10.1016/j.jaci.2025.01.045
BibTeX
@article{McLaren2025,
author = {McLaren, Julie and Chon, Yun and Gorski, Kevin S and Bernstein, Jonathan A and Corren, Jonathan and Hayama, Koremasa and Jain, Vipul and Lima, Hermenio and Sofen, Howard and Ponnarambil, Sandhia and Molfino, Nestor A and Maurer, Marcus},
title = {Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
volume = {155},
number = {6},
pages = {1945--1956},
doi = {10.1016/j.jaci.2025.01.045}
}
EUVIMED